Amylyx Pharma to present topline data from Phase 3 LUCIDITY trial of avexitide
Amylyx Pharmaceuticals will present topline data from its Phase 3 LUCIDITY clinical trial of avexitide, an investigational treatment for post-bariatric hypoglycemia, at the ObesityWeek® 2026 Annual Meeting. The trial met its primary efficacy endpoint.